美托洛尔联合氯沙坦钾氢氯噻嗪治疗老年高血压合并慢性心衰的临床研究

目的 探究美托洛尔联合氯沙坦钾氢氯噻嗪治疗老年高血压合并慢性心衰的临床效果。方法 选择2020年6月-2021年6月阳春市人民医院收治的76例老年高血压合并慢性心衰患者为研究对象,采用随机抽签法将其随机分为对照组和观察组,每组各38例。两组均予以常规强心、利尿、降压治疗,在此基础上,对照组加用美托洛尔,观察组加用美托洛尔联合氯沙坦钾氢氯噻嗪治疗,比较两组治疗总有效率以及治疗前、治疗3个月患者血压、心率、血清BNP、左心室射血分数（LVEF）变化情况。结果 观察组治疗总有效率显著高于对照组（P<0.05）。治疗前,两组的血压（收缩压、舒张压）、心率、血清BNP、LVEF检测值比较差异无统计学意义（P>0.05）,治疗3个月,两组上述血压、心率、各项心功能指标均较治疗前有改善,且观察组明显优于对照组（P<0.05）。两组药物不良反应发生率比较差异无统计学意义（P>0.05）。结论 美托洛尔联合氯沙坦钾氢氯噻嗪治疗老年高血压合并慢性心衰能够显著提升整体疗效,有效改善患者的血压水平和心功能,且安全性良好,值得临床进一步研究和推广。     

氢氯噻嗪联合氯沙坦治疗高血压合并糖尿病效果研究

目的探讨使用氢氯噻嗪联合氯沙坦治疗高血压合并糖尿病的临床效果,为临床治疗提供参考资料。方法选择2014年1—12月在本院住院的高血压合并糖尿病患者158例随机分为试验组和对照组;在使用胰岛素控制血糖的情况下,试验组使用氯沙坦联合氢氯噻嗪,对照组使用氯沙坦进行血压控制。计量资料采用t检验,计数资料采用χ2检验,P0.05为差异有统计学意义。结果治疗1、2、3、4周后,试验组的收缩压及舒张压[(147.40±19.19)、(138.18±19.81)、(127.83±20.95)、(121.55±21.08)mm Hg(1 mm Hg=0.133 k Pa)与(101.87±15.58)、(92.63±15.86)、(83.16±17.18)、(75.87±17.42)mm Hg]均显著低于对照组[(156.21±19.24)、(150.79±19.53)、(145.75±19.97)、(140.41±20.01)mm Hg与(106.14±14.4)、(100.99±14.43)、(96.14±15.14)、(91.57±14.97)mm Hg],差异均有统计学意义(均P0.05)。治疗后,试验组的血尿素氮与尿微量白蛋白[(5.67±1.38)mmol/L与(25.47±5.06)mg·g-1·Cr-1]均显著低于对照组[(6.25±1.04)mmol/L与(38.73±5.98)mg·g-1·Cr-1],差异均有统计学意义(均P0.05)。结论临床上采用氢氯噻嗪联合氯沙坦治疗高血压合并糖尿病患者治疗效果较好,能够有效地控制患者血压,降低治疗过程中药物对其他器官的损害,能够有效改善患者预后,可以考虑在临床加以推广应用。     

复方利血平氢氯噻嗪片制剂工艺和质量标准分析

目的分析复方利血平氢氯噻嗪片制剂工艺和质量标准。方法利用加速试验、影响因素试验、稳定性试验等对比试验,研究复方利血平氢氯噻嗪片薄膜包衣的制剂工艺,并比较糖衣片与薄膜包衣片的不同理化性质。结果试验显示,复方利血平氢氯噻嗪片制剂采取薄膜包衣会具有更高的稳定性。结论复方利血平氢氯噻嗪片的处方标准是30mg利血平、3.1g氢氯噻嗪、1.0g维生素B1、1.0g维生素B6、30g三硅酸镁、4.2g硫酸双肼屈嗪、1.0g混旋泛酸钙、30g氯化钾、2.1g盐酸异丙嗪,加适量辅料制成数量为1000的片剂。其中,利血平含量范围处于标示量的80.0%-120.0%,氢氯噻嗪、罗通定、氯化钾的含量为标示量的85.0%-115.0%。     

氯沙坦、氢氯噻嗪、氨氯地平联合美托洛尔治疗难治性高血压效果分析

目的探究氯沙坦、氢氯噻嗪、氨氯地平联合美托洛尔治疗难治性高血压患者效果。方法选择上街区人民医院2010年8月至2013年8月治疗的80例难治性高血压患者为观察对象,应用随机数字表法将患者分为对照组和试验组,每组各40例,对照组患者每日口服10mg/d氢氯噻嗪、50mg/d氯沙坦、酒石酸美托洛尔缓释片25mg/d治疗,试验组患者则每日在上述治疗的基础上给予苯磺酸氨氯地平5mg/d治疗,比较2组患者临床疗效和药物不良反应。结果治疗前,在坐位收缩压和坐位舒张压方面,2组患者差异无统计学意义,P0.05,治疗3月,在坐位收缩压和坐位舒张压方面,试验组患者显著优于对照组患者的,差异有统计学意义,P0.05。2组患者在不良反应发生方面差异无统计学意义(P0.05)。结论氯沙坦、氢氯噻嗪、氨氯地平联合美托洛尔治疗难治性高血压患者临床疗效确切,具有效果好、安全可靠和不良反应少等特点,值得推广运用。     

厄贝沙坦氢氯噻嗪片治疗原发性高血压的疗效探讨

目的 ：分析厄贝沙坦氢氯噻嗪片治疗原发性高血压的疗效。方法：选择2013年5月—2013年11月36例原发性高血压患者,随机分成观察组与对照组,每组18例。其中观察组患者采用厄贝沙坦氢氯噻嗪片进行治疗,对照组中的患者采用口服厄贝沙坦进行治疗。两组患者的疗程为一个月。结果：经过一个疗程的治疗之后,对观察组与对照组进行比较,两组患者的差异具有统计学意义（P〈0.05）。结论：使用厄贝沙坦氢氯噻嗪片治疗原发性高血压的疗效显著,能够有效的控制血压,充分的减轻患者的不良反应,值得临床推广。     

缬沙坦联合氢氯噻嗪片治疗60例原发性高血压临床疗效

目的：为了探究临床有效治疗原发性高血压的可靠方法,从而为原发性高血压的相关其他研究提供借鉴依据。方法：本次选取的研究比例均为2009年12月至2013年1月期间,我院收治的原发性高血压患者,患者共计120例,随机对患者进行分组,分成治疗组和对照组,每组60例。分别采用缬沙坦联合氢氯噻嗪片治疗和单独缬沙坦治疗,观察并比较两组患者实施不同治疗方法后的临床治疗整体效果。结果：临床治疗总有效率组间比较,治疗组患者的临床治疗总有效率显著的高于对照组,且数据比较差异具有显著的统计学意义（χ^2=8.5389,p=0.0035）。结论：在临床针对原发性高血压患者实施治疗的实践过程中,采用缬沙坦联合氢氯噻嗪片治疗方法的临床效果显著,是临床治疗原发性高血压的可靠选择。     

厄贝沙坦氢氯噻嗪片治疗原发性高血压临床观察

目的研究分析采用厄贝沙坦氢氯噻嗪片对于原发性高血压的临床治疗效果。方法选择我院2012年12月—2013年12月收治的120例原发性高血压患者,将所有患者按照随机数字法分为观察组和对照组,每组各60例。对照组给予患者厄贝沙坦片治疗,观察组给予患者厄贝沙坦氢氯噻嗪片治疗。对比观察两组患者的临床治疗效果、治疗前后收缩压与舒张压的变化情况以及术后不良反应发生情况。结果观察组患者在治疗后,总有效率达到90.00%,明显高于对照组患者的78.33%,差异具有统计学意义（P〈0.05）。两组患者在治疗后舒张压与收缩压相比于治疗前均得到明显改善,观察组在治疗后收缩压与舒张压的改善程度明显优于对照组,差异具有统计学意义（P〈0.05）。两组患者不良反应发生率比较差异有统计学意义（P〉0.05）。结论对于原发性高血压患者采取厄贝沙坦氢氯噻嗪片的治疗效果显著,能够有效改善患者收缩压和舒张压情况,值得临床推广运用。     

厄贝沙坦氢氯噻嗪片对血压晨峰及左心室质量相关参数的影响

目的 观察厄贝沙坦氢氯噻嗪片对中老年原发性高血压患者血压晨峰(MBPS)及左心室质量(LVM)相关参数的影响.方法 选择120例轻中度原发性高血压患者,口服厄贝沙坦氢氯噻嗪片150 ms/12.5 mg,4～8周不达标者剂量加倍,治疗12个月,应用动态血压监测(ABPM)评价治疗前后MBPS的变化,应用超声心动图评价LVM相关参数的变化.结果 (1)经厄贝沙坦氢氯噻嗪片治疗后,MBPS(+)的患者减少,MBPS(-)的患者增多,与治疗前比较差异有统计学意义(P<0.01).(2)治疗后MBPS(+)患者晨峰程度较治疗前明显降低[收缩压(SBP)差值(16.1±1.8)mm Hg(1 mm Hg=0.133 kPa)比(29.4±2.8)mm Hg,舒张压(DBP)差值(10.2±2.3)mm Hg比(21.2±2.2)mm Hg,P<0.01],而MBPS(-)患者晨峰程度较治疗前无明显下降[SBP差值(11.2±2.4)mm Hg比(10.1±1.2)mm Hg,DBP差值(5.9±1.9)mm Hg比(6.8±3.2)mm Hg].(3)MBPS(+)和MBPS(-)患者治疗后LVM相关参数较治疗前均明显减小,且MBPS(+)患者治疗后左心室后壁厚度、LVM、LVM指数与MBPS(-)患者治疗后比较差异有统计学意义(P<0.05).结论 厄贝沙坦氢氯噻嗪片能有效遏制MBPS的发生,降低晨峰程度,并能逆转左心室肥厚.     

缬沙坦联合氢氯噻嗪治疗原发性高血压临床分析

目的探讨缬沙坦联合氢氯噻嗪治疗原发性高血压的疗效及安全性。方法41例原发性高血压患者,每日口服缬沙坦80mg、氢氯噻嗪25mg,疗程8周。监测血压和心率,并于治疗前和治疗后分别检查超声心动图,测量左室舒张末期内径(LVDd)、室间隔厚度(IVST)及左室后壁厚度(PWT),检查血尿酸、肌酐、谷丙转氨酶、钾、钠、氯。结果治疗8周后血压、左心室心肌重量及重量指数较治疗前均明显降低(P<0.05)。结论缬沙坦联合氢氯噻嗪治疗原发性高血压安全、有效、长效。     

洛汀新合用氢氯噻嗪治疗原发性高血压疗效观察

目的 探讨洛汀新合用氩氯噻嗪治疗原发性高血压效果。方法 50例原发性高血压患者,每日服洛汀新10mg、氩氯噻嗪25mg,疗程10周,监测血压和心率,并于治疗前和治疗后分别检查超声心动图,测量LVDd、IVST及PWT,查血肌酐、尿素氮,血钾、钠、氯。结果 治疗后血压、左心室心肌重量及重量指数都明显降低。结论 洛汀新合用氢氯噻嗪治疗原发性高血压效果良好。     

老年高血压采用厄贝沙坦氢氯噻嗪片的研究

目的 研究分析老年高血压患者采用厄贝沙坦联合氢氯噻嗪片临床治疗效果.方法 选取天津市西青医院100例患高血压老年患者作为本次研究对象,人院时间为2019年2-10月,按照随机数字表法对患者进行分组,分别设立对照组和观察组,每组各50例.服用厄贝沙坦进行治疗为对照组,服用厄贝沙坦联合氢氯噻嗪片进行治疗为观察组,比较两组临...     

苯磺酸氨氯地平片联合氢氯噻嗪治疗老年性高血压临床观察

我院自2005年1月～2006年1月，应用苯磺酸氨氯地平片联合氢氯噻嗪治疗老年性2级、3级高血压患者56例取得良好疗效。现报道如下。[第一段]     

卡托普利联合氢氯噻嗪片治疗原发性高血压的临床观察

目的深入分析和研究使用卡托普利联合氢氯噻嗪片治疗原发性高血压的临床效果。方法收集2009年9月——2012年6月来我院接受治疗的原发性高血压病患74列,将病患随机分为观察组和对照组各37例病患。对照组在治疗过程当中只是服用卡托普利药物;观察组选择复合型治疗在药物的选择上使用卡托普利和氢氯噻嗪两种药物。结果观察组治疗情况要显著优于对照组,差异具有明显统计学意义(P<0.05)。结论使用卡托普利联合氢氯噻嗪片治疗原发性高血压效果要比单独使用卡托普利要好,在临床中可广泛使用。     

厄贝沙坦氢氯噻嗪片对血压晨峰及左心室质量相关参数的影响

Objective To investigate the influence of combined irbesartan/hydrochlomthiazide on morning blood pressure surge(MBPS)and left ventricular mass(LVM) in essential hypertension.Methods After 4-8 weeks' run-in period,if blood pressure wagn't up to the standard,the 120 patients were given irbesartan/hydrochlorothiazide once daily from 150 mg/12.5 mg for 12 months to 300 mg/25mg for another 12 months.MBPS was conducted by arnbuhry blood pressure monitoring(ABPM)and LVM was determined by echocardiography at the end of placebo baseline and 12 months later.Results (1)After treatment the patients with MBPS(+)decreased and patients with MBPS(-) increased.(2)After treatment the extents of MBPS were reduced in MBPS(+)patients[systolic blood pressure(SBP)difference(16.1±1.8)mm Hg(1mm Hg=0.133 kPa)vs(29.4±2.8)mm Hg,diastolic blood pressure(DBP)difference(10.2±2.3)mm Hg vs(21.2±2.2)mm Hg,P<0.01]with little change in MBPS(-)patients[SBP difference(11.2±2.4)mm Hg vs(10.1±1.2)mm Hg,DBP difference(5.9±1.9)mm Hg vs(6.8±3.2)mm Hg]compared with before treatment.(3)LVM indexes of all patients were significantly reduced.Conclusion Irbesartan/hydrochlorothiazide can effectively attenuate the extent of MBPS, and has advantages on reversing left ventricular hypertrophy.     

厄贝沙坦氢氯噻嗪片对血压晨峰及左心室质量相关参数的影响

Objective To investigate the influence of combined irbesartan/hydrochlomthiazide on morning blood pressure surge(MBPS)and left ventricular mass(LVM) in essential hypertension.Methods After 4-8 weeks' run-in period,if blood pressure wagn't up to the standard,the 120 patients were given irbesartan/hydrochlorothiazide once daily from 150 mg/12.5 mg for 12 months to 300 mg/25mg for another 12 months.MBPS was conducted by arnbuhry blood pressure monitoring(ABPM)and LVM was determined by echocardiography at the end of placebo baseline and 12 months later.Results (1)After treatment the patients with MBPS(+)decreased and patients with MBPS(-) increased.(2)After treatment the extents of MBPS were reduced in MBPS(+)patients[systolic blood pressure(SBP)difference(16.1±1.8)mm Hg(1mm Hg=0.133 kPa)vs(29.4±2.8)mm Hg,diastolic blood pressure(DBP)difference(10.2±2.3)mm Hg vs(21.2±2.2)mm Hg,P<0.01]with little change in MBPS(-)patients[SBP difference(11.2±2.4)mm Hg vs(10.1±1.2)mm Hg,DBP difference(5.9±1.9)mm Hg vs(6.8±3.2)mm Hg]compared with before treatment.(3)LVM indexes of all patients were significantly reduced.Conclusion Irbesartan/hydrochlorothiazide can effectively attenuate the extent of MBPS, and has advantages on reversing left ventricular hypertrophy.     

厄贝沙坦氢氯噻嗪片对血压晨峰及左心室质量相关参数的影响

Objective To investigate the influence of combined irbesartan/hydrochlomthiazide on morning blood pressure surge(MBPS)and left ventricular mass(LVM) in essential hypertension.Methods After 4-8 weeks' run-in period,if blood pressure wagn't up to the standard,the 120 patients were given irbesartan/hydrochlorothiazide once daily from 150 mg/12.5 mg for 12 months to 300 mg/25mg for another 12 months.MBPS was conducted by arnbuhry blood pressure monitoring(ABPM)and LVM was determined by echocardiography at the end of placebo baseline and 12 months later.Results (1)After treatment the patients with MBPS(+)decreased and patients with MBPS(-) increased.(2)After treatment the extents of MBPS were reduced in MBPS(+)patients[systolic blood pressure(SBP)difference(16.1±1.8)mm Hg(1mm Hg=0.133 kPa)vs(29.4±2.8)mm Hg,diastolic blood pressure(DBP)difference(10.2±2.3)mm Hg vs(21.2±2.2)mm Hg,P<0.01]with little change in MBPS(-)patients[SBP difference(11.2±2.4)mm Hg vs(10.1±1.2)mm Hg,DBP difference(5.9±1.9)mm Hg vs(6.8±3.2)mm Hg]compared with before treatment.(3)LVM indexes of all patients were significantly reduced.Conclusion Irbesartan/hydrochlorothiazide can effectively attenuate the extent of MBPS, and has advantages on reversing left ventricular hypertrophy.     

厄贝沙坦氢氯噻嗪片对血压晨峰及左心室质量相关参数的影响

Objective To investigate the influence of combined irbesartan/hydrochlomthiazide on morning blood pressure surge(MBPS)and left ventricular mass(LVM) in essential hypertension.Methods After 4-8 weeks' run-in period,if blood pressure wagn't up to the standard,the 120 patients were given irbesartan/hydrochlorothiazide once daily from 150 mg/12.5 mg for 12 months to 300 mg/25mg for another 12 months.MBPS was conducted by arnbuhry blood pressure monitoring(ABPM)and LVM was determined by echocardiography at the end of placebo baseline and 12 months later.Results (1)After treatment the patients with MBPS(+)decreased and patients with MBPS(-) increased.(2)After treatment the extents of MBPS were reduced in MBPS(+)patients[systolic blood pressure(SBP)difference(16.1±1.8)mm Hg(1mm Hg=0.133 kPa)vs(29.4±2.8)mm Hg,diastolic blood pressure(DBP)difference(10.2±2.3)mm Hg vs(21.2±2.2)mm Hg,P<0.01]with little change in MBPS(-)patients[SBP difference(11.2±2.4)mm Hg vs(10.1±1.2)mm Hg,DBP difference(5.9±1.9)mm Hg vs(6.8±3.2)mm Hg]compared with before treatment.(3)LVM indexes of all patients were significantly reduced.Conclusion Irbesartan/hydrochlorothiazide can effectively attenuate the extent of MBPS, and has advantages on reversing left ventricular hypertrophy.     

厄贝沙坦氢氯噻嗪片对血压晨峰及左心室质量相关参数的影响

Objective To investigate the influence of combined irbesartan/hydrochlomthiazide on morning blood pressure surge(MBPS)and left ventricular mass(LVM) in essential hypertension.Methods After 4-8 weeks' run-in period,if blood pressure wagn't up to the standard,the 120 patients were given irbesartan/hydrochlorothiazide once daily from 150 mg/12.5 mg for 12 months to 300 mg/25mg for another 12 months.MBPS was conducted by arnbuhry blood pressure monitoring(ABPM)and LVM was determined by echocardiography at the end of placebo baseline and 12 months later.Results (1)After treatment the patients with MBPS(+)decreased and patients with MBPS(-) increased.(2)After treatment the extents of MBPS were reduced in MBPS(+)patients[systolic blood pressure(SBP)difference(16.1±1.8)mm Hg(1mm Hg=0.133 kPa)vs(29.4±2.8)mm Hg,diastolic blood pressure(DBP)difference(10.2±2.3)mm Hg vs(21.2±2.2)mm Hg,P<0.01]with little change in MBPS(-)patients[SBP difference(11.2±2.4)mm Hg vs(10.1±1.2)mm Hg,DBP difference(5.9±1.9)mm Hg vs(6.8±3.2)mm Hg]compared with before treatment.(3)LVM indexes of all patients were significantly reduced.Conclusion Irbesartan/hydrochlorothiazide can effectively attenuate the extent of MBPS, and has advantages on reversing left ventricular hypertrophy.     

厄贝沙坦氢氯噻嗪片对血压晨峰及左心室质量相关参数的影响

Objective To investigate the influence of combined irbesartan/hydrochlomthiazide on morning blood pressure surge(MBPS)and left ventricular mass(LVM) in essential hypertension.Methods After 4-8 weeks' run-in period,if blood pressure wagn't up to the standard,the 120 patients were given irbesartan/hydrochlorothiazide once daily from 150 mg/12.5 mg for 12 months to 300 mg/25mg for another 12 months.MBPS was conducted by arnbuhry blood pressure monitoring(ABPM)and LVM was determined by echocardiography at the end of placebo baseline and 12 months later.Results (1)After treatment the patients with MBPS(+)decreased and patients with MBPS(-) increased.(2)After treatment the extents of MBPS were reduced in MBPS(+)patients[systolic blood pressure(SBP)difference(16.1±1.8)mm Hg(1mm Hg=0.133 kPa)vs(29.4±2.8)mm Hg,diastolic blood pressure(DBP)difference(10.2±2.3)mm Hg vs(21.2±2.2)mm Hg,P<0.01]with little change in MBPS(-)patients[SBP difference(11.2±2.4)mm Hg vs(10.1±1.2)mm Hg,DBP difference(5.9±1.9)mm Hg vs(6.8±3.2)mm Hg]compared with before treatment.(3)LVM indexes of all patients were significantly reduced.Conclusion Irbesartan/hydrochlorothiazide can effectively attenuate the extent of MBPS, and has advantages on reversing left ventricular hypertrophy.     

厄贝沙坦氢氯噻嗪片对血压晨峰及左心室质量相关参数的影响

Objective To investigate the influence of combined irbesartan/hydrochlomthiazide on morning blood pressure surge(MBPS)and left ventricular mass(LVM) in essential hypertension.Methods After 4-8 weeks' run-in period,if blood pressure wagn't up to the standard,the 120 patients were given irbesartan/hydrochlorothiazide once daily from 150 mg/12.5 mg for 12 months to 300 mg/25mg for another 12 months.MBPS was conducted by arnbuhry blood pressure monitoring(ABPM)and LVM was determined by echocardiography at the end of placebo baseline and 12 months later.Results (1)After treatment the patients with MBPS(+)decreased and patients with MBPS(-) increased.(2)After treatment the extents of MBPS were reduced in MBPS(+)patients[systolic blood pressure(SBP)difference(16.1±1.8)mm Hg(1mm Hg=0.133 kPa)vs(29.4±2.8)mm Hg,diastolic blood pressure(DBP)difference(10.2±2.3)mm Hg vs(21.2±2.2)mm Hg,P<0.01]with little change in MBPS(-)patients[SBP difference(11.2±2.4)mm Hg vs(10.1±1.2)mm Hg,DBP difference(5.9±1.9)mm Hg vs(6.8±3.2)mm Hg]compared with before treatment.(3)LVM indexes of all patients were significantly reduced.Conclusion Irbesartan/hydrochlorothiazide can effectively attenuate the extent of MBPS, and has advantages on reversing left ventricular hypertrophy.